Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests £230
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  3. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  4. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  8. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  9. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  10. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  11. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  12. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  13. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  14. Healy LM, et al. 2020. Glia. 68:811. PubMed
  15. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  16. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  17. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  18. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  19. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  20. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  21. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  22. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  23. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  24. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  25. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  26. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  27. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  28. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  29. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  30. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  31. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  32. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  33. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  34. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  35. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  36. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  37. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  38. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  39. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  40. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  41. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  42. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  43. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  44. Toomer G, et al. 2022. Viruses. 14:. PubMed
  45. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  46. Price P, et al. 2014. J Virol. 88:10840. PubMed
  47. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  48. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  49. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  50. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  51. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  52. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  53. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  54. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  55. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  56. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  57. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  58. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  59. Munoz MA, et al. 2021. Elife. 10:. PubMed
  60. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  61. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  62. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  63. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  64. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  65. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  66. Yu X, et al. 2021. Nature. 594:560. PubMed
  67. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  68. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  69. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  70. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  71. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  72. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  73. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  74. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  75. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  76. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  77. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  78. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  79. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  80. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  81. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  82. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  83. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  84. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  85. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  86. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  87. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  88. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  89. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  90. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  91. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  92. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  93. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  94. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  95. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  96. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  97. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  98. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  99. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  100. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  101. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  102. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  103. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  104. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  105. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  106. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  107. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  108. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  109. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  110. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  111. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  112. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  113. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  114. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  115. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  116. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  117. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  118. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  119. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  120. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  121. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  122. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  123. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  124. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  125. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  126. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  127. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  128. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  129. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  130. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  131. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  132. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  133. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  134. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  135. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  136. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  137. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  138. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  139. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  140. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  141. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  142. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  143. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  144. Romine KA, et al. 2021. Cancer Discov. . PubMed
  145. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  146. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  147. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  148. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  149. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  150. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  151. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  152. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  153. Köchl R, et al. 2020. Elife. 9:00. PubMed
  154. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  155. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  156. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  157. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  158. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  159. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  160. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  161. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  162. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  163. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  164. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  165. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  166. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  167. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  168. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  169. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  170. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  171. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  172. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  173. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  174. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  175. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  176. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  177. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  178. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  179. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  180. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  181. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  182. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  183. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  184. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  185. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  186. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  187. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  188. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  189. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  190. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  191. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  192. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  193. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  194. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  195. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  196. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  197. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  198. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  199. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  200. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  201. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  202. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  203. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  204. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  205. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  206. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  207. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  208. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  209. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  210. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  211. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  212. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  213. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  214. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  215. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  216. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  217. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  218. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  219. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  220. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  221. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  222. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  223. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  224. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  225. Barington L, et al. 2022. Cells. 11:. PubMed
  226. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  227. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  228. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  229. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  230. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  231. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  232. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  233. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  234. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  235. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  236. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  237. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  238. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  239. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  240. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  241. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  242. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  243. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  244. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  245. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  246. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  247. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  248. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  249. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  250. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  251. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  252. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  253. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  254. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  255. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  256. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  257. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  258. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  259. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  260. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  261. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  262. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  263. Kumar S, et al. 2022. Gut. . PubMed
  264. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  265. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  266. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  267. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  268. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  269. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  270. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  271. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  272. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  273. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  274. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  275. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  276. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  277. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  278. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  279. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  280. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  281. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  282. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  283. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  284. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  285. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  286. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  287. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  288. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  289. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  290. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  291. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  292. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  293. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  294. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  295. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  296. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  297. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  298. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  299. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  300. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  301. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  302. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  303. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  304. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  305. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  306. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  307. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  308. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  309. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  310. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  311. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  312. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  313. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  314. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  315. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  316. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  317. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  318. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  319. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  320. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  321. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  322. Yuan C, et al. 2018. iScience. 11:13. PubMed
  323. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  324. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  325. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  326. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  327. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  328. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  329. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  330. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  331. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  332. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  333. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  334. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  335. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  336. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  337. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  338. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  339. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  340. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  341. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  342. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  343. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  344. Spath S, et al. 2022. iScience. 25:104998. PubMed
  345. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  346. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  347. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  348. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  349. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  350. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  351. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  352. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  353. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  354. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  355. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  356. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  357. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  358. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  359. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  360. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  361. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  362. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  363. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  364. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  365. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  366. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  367. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  368. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  369. Li J, et al. 2015. Cancer Res. 75:508. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 8    Revision Date: 01/27/2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account